MARKET

ISEE

ISEE

IVERIC bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.110
0.000
0.00%
Closed 16:00 09/18 EDT
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.141
LOW
1.110
VOLUME
116.36K
TURNOVER
--
52 WEEK HIGH
2.570
52 WEEK LOW
1.020
MARKET CAP
46.13M
P/E (TTM)
0.7124
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ISEE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ISEE News

  • IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference
  • Business Wire.1d ago
  • IVERIC bio to Host Inaugural Gene Therapy R&D Investor Day on September 13, 2019
  • Business Wire.09/04 13:00
  • IVERIC bio (ISEE) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
  • Seeking Alpha - Article.08/15 18:23
  • IVERIC bio to Present at the Wedbush PacGrow Healthcare Conference
  • Business Wire.08/07 13:00

More

Industry

Biotechnology & Medical Research
-0.89%
Pharmaceuticals & Medical Research
-0.15%

Hot Stocks

Name
Price
%Change

About ISEE

IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.
More

Webull offers IVERIC bio Inc (ISEE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.